CClinicalTrials.gg
RecruitingNCT07050628Updated Aug 25, 2026

Assessment of CSF Shunt Flow During Activities of Daily Living and Sleep With a Thermal Measurement Device

An interventional study of wireless thermal anisotropy measurement device in Hydrocephalus, sponsored by Rhaeos, Inc.. Recruiting at 2 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Rhaeos, Inc. · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Study summary

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during activities of daily living and sleep

02

Conditions studied

  • Hydrocephalus

Browse trials for

03

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Existing ventricular CSF shunt
  2. (Cohort A) A history of stable ventricular size, no shunt revision in the previous 2 years, and no current symptoms of shunt failure
  3. (Cohort B) A shunt revision in the previous 7 days and the investigator judges that the patient will likely be discharged within 4 days of the enrollment date
  4. Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device
  5. Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes)
  6. Subject is at least 5 years old but \< 22 years old

Exclusion criteria

Exclusion Criteria:

  1. Shunt is not palpable or depth of shunt where the device will be placed is greater than 4 mm per ultrasound evaluation
  2. Presence of an interfering open wound or edema in the study device measurement region
  3. Subject-reported history of serious adverse skin reactions to silicone-based adhesives
  4. Investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable
  5. Investigator judges that the subject is unlikely to successfully take reliable measurements at home
  6. Investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance
  7. Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject
  8. Prior enrollment in this study
  9. Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    No Recent Revision

    Pediatric hydrocephalus patients with an existing ventricular CSF shunt and a history of stable ventricular size, no shunt revision in the previous 2 years, and no current symptoms of shunt failure will be enrolled.

    Device: wireless thermal anisotropy measurement device

  • Experimental
    Recent Revision

    Pediatric hydrocephalus patients with an existing ventricular CSF shunt and a shunt revision in the previous 7 days who the investigator judges will likely be discharged within 4 days of the enrollment date will be enrolled.

    Device: wireless thermal anisotropy measurement device

Interventions

  • Devicewireless thermal anisotropy measurement device

    Wireless wearable thermal anisotropy measurement device designed for use at home will be provided to study subjects in both study arms

05

What researchers measure

Primary outcomes

  1. Adverse Device Effects

    The co-primary endpoints in this study are the rate of ADEs and SADEs that occur per wear hour.

    Time frame: 30 days

Secondary outcomes

  1. ADEs and SADEs per wear period

    rate of ADEs and SADEs per wear period

    Time frame: 30 days

  2. ADEs and SADEs per subject

    rate of ADEs and SADEs per subject;

    Time frame: 30 days

  3. ADEs and SADEs that preclude the continued use of the study device

    rate of ADEs and SADEs that preclude the continued use of the study device

    Time frame: 30 days

  4. Device deficiencies resulting in incomplete monitoring data

    percent of device deficiencies resulting in incomplete monitoring data

    Time frame: 30 days

  5. Local skin reactions per wear session;

    number of local skin reactions per wear session;

    Time frame: 30 days

  6. Usability score

    usability score based on post-study survey (1 = easy to use; 5 = difficult to use)

    Time frame: 30 days

06

Study locations

2 of 2 sites recruiting
  • Rhaeos Inc.
    Chicago, Illinois 60642, United States
    Recruiting
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07050628
Lead sponsor
Rhaeos, Inc.
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Nov 10, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Richard C Webb, PhD
Contact
cwebb@rhaeos.com
855-814-3569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion